BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34925247)

  • 1. Attenuation Value in Adrenal Incidentalomas: A Longitudinal Study.
    Ceccato F; Tizianel I; Voltan G; Maggetto G; Merante Boschin I; Quaia E; Crimì F; Scaroni C
    Front Endocrinol (Lausanne); 2021; 12():794197. PubMed ID: 34925247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; Cuesta Hernández M; Sampedro Núñez MA; Marazuela M
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?
    Sane T; Schalin-Jäntti C; Raade M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2077-83. PubMed ID: 22492870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G; Fanelli F; Zavatta G; Ricci Bitti S; Mezzullo M; Repaci A; Pelusi C; Gambineri A; Altieri P; Mosconi C; Balacchi C; Golfieri R; Cosentino ER; Borghi C; Vicennati V; Pasquali R; Pagotto U
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5519-5528. PubMed ID: 31381072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Tsagarakis S; Terzolo M; Tabarin A; Sahdev A; Newell-Price J; Pelsma I; Marina L; Lorenz K; Bancos I; Arlt W; Dekkers OM
    Eur J Endocrinol; 2023 Jul; 189(1):G1-G42. PubMed ID: 37318239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
    Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
    J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P; Orsolini F; Benelli E; Agretti P; Vitti P; Di Cosmo C; Tonacchera M
    Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
    Yener S; Baris M; Peker A; Demir O; Ozgen B; Secil M
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):425-432. PubMed ID: 28656620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden.
    Olsen H; Nordenström E; Bergenfelz A; Nyman U; Valdemarsson S; Palmqvist E
    Endocrine; 2012 Aug; 42(1):164-73. PubMed ID: 22350586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Capacity of CT Volumetry to Identify Autonomous Cortisol Secretion in Incidental Adrenal Adenomas.
    Olmos R; Mertens N; Vaidya A; Uslar T; Fernandez P; Guarda FJ; Zúñiga Á; San Francisco I; Huete A; Baudrand R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1946-e1953. PubMed ID: 35020922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subclinical Cushing's syndrome in adrenal incidentaloma.
    Terzolo M; Osella G; Alì A; Borretta G; Cesario F; Paccotti P; Angeli A
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):89-97. PubMed ID: 9509073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M; Mínguez Ojeda C; Sánchez Ramírez MN; Gómez Dos Santos V; Pascual-Corrrales E; Fernández-Argüeso M
    Endocrine; 2022 Oct; 78(1):142-150. PubMed ID: 35751779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study.
    Di Dalmazi G; Vicennati V; Pizzi C; Mosconi C; Tucci L; Balacchi C; Cosentino ER; Paolisso P; Fanelli F; Gambineri A; Pelusi C; Repaci A; Garelli S; Galiè N; Borghi C; Golfieri R; Pagotto U
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
    Rossi R; Tauchmanova L; Luciano A; Di Martino M; Battista C; Del Viscovo L; Nuzzo V; Lombardi G
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Arlt W; Bancos I; Dralle H; Newell-Price J; Sahdev A; Tabarin A; Terzolo M; Tsagarakis S; Dekkers OM
    Eur J Endocrinol; 2016 Aug; 175(2):G1-G34. PubMed ID: 27390021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.
    Remde H; Kranz S; Morell SM; Altieri B; Kroiss M; Detomas M; Fassnacht M; Deutschbein T
    Front Endocrinol (Lausanne); 2023; 14():1123132. PubMed ID: 37223045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
    Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice.
    Hong AR; Kim JH; Park KS; Kim KY; Lee JH; Kong SH; Lee SY; Shin CS; Kim SW; Kim SY
    Eur J Endocrinol; 2017 Dec; 177(6):475-483. PubMed ID: 28870984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol secretion from adrenal adenomas discovered as incidentalomas is responsive to ACTH.
    Olsen H; Olofsson L; Mjöman M
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):335-41. PubMed ID: 23865937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas.
    Debono M; Bradburn M; Bull M; Harrison B; Ross RJ; Newell-Price J
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4462-70. PubMed ID: 25238207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.